TD Cowen analyst Brendan Smith raised the firm’s price target on Halozyme to $65 from $59 and keeps a Buy rating on the shares. The firm said its Q2 EPS beat was driven by higher-than-expected collab revenues and ENHANZE API sales.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO: